It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We design and optimize linkers and payloads that define ADC performance, helping you create safer, more selective therapies through collaborative, science- driven innovation.
Introducing a novel payload-focused approach to next generation ADC development.
Sygnature Discovery’s NewPath ADC platform delivers fully integrated and collocated solutions for antibody drug conjugates (ADCs). Our multidisciplinary teams combine medicinal chemistry, protein sciences, and both in vitro and in vivo assessment, including DMPK to create ADCs that perform.
Most providers follow a conventional ADC development path. We take a different route. Sygnature Discovery prioritizes payload optimization to improve efficacy and selectivity, maximizing therapeutic benefit. The result? Better-performing ADCs that help you succeed.
How Can We Help?
We believe our small molecule focus offers an advantage when it comes to ADCs. After all, the linker and payload define an ADC’s performance, and that’s where we excel.
While we can produce antibodies, conjugate, analyze, and screen for developability, it’s our extensive capabilities in the design, synthesis and optimization aspects of both the linker and the payload that really sets us apart.
ADC payload development is still evolving, but our partners already use our platform to advance safer, more selective ADCs toward the clinic.
Our Solutions
Our comprehensive ADC framework tackles challenges from early design through IND-enabling studies. We focus on developability, safety profiling, and clinical progression, integrating in vitro and in vivo profiling to optimize potency, efficacy, and safety, leading to better patient outcomes.
Big ADC problem? Small Molecule Solutions
Our holistic approach to ADC development draws on expertise in four key areas:
Medicinal Chemistry Focused ADC Optimization
Even a small chemical or steric change to the payload can dramatically impact selectivity, development, and tolerability.
DMPK Profiling for Payloads
Understanding metabolic and PK profiles ensures optimal safety, as payload clearance is critical to limiting systemic toxicity.
Synergistic Optimization
Next -generation ADCs aren’t built in parts (antibody, linker, payload); they’re optimized as a whole. Understanding the complete entity is essential to delivering next generation ADCs.
Repurposing Small Molecule Assets
Transforming clinical small molecules into ADC payloads creates opportunities for dual specificity and may revive compounds that previously failed due to DMPK or toxicity issues.
Design, Make, Test, Analyze
We bring small molecule thinking to large molecule discovery.
Our chemistry expertise drives optimization of antibodies, conjugation techniques, linkers, and payloads, while our protein science and biology teams ensure a streamlined path from designing your antibody drug conjugate to testing it.
Our ADC design & make capabilities
Antibody expression and purification
Linker payload synthesis
Conjugation
QC/Characterisation
Our ADC test & analyze capabilities
Biophysical Screening
in-vitro PD analysis
in vitro DMPK analysis
in vivo Analysis
Developability
Our team
Our Oncology Lead Consultant
Allan Jordan, PhD
Vice President, Oncology Drug Discovery
Allan joined Sygnature Discovery in February 2019 and serves as Vice President of Oncology Drug Discovery. With more than 25 years of experience in medicinal chemistry and drug discovery, Allan has an outstanding track record of advancing compounds into clinical trials across multiple therapeutic areas. Before joining Sygnature, he spent nine years as Head of Chemistry at the Cancer Research UK Manchester Institute Drug Discovery Unit. During his time at…
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Antibody-drug conjugates (ADCs) represent an important approach to targeted cancer therapy, combining the…
Blog
FAQs
Our ADC platform brings together experienced teams across multiple disciplines to initiate and evolve ADC discovery campaigns. We specialize in payload-focused development and have extensive capabilities to optimize therapeutic windows and biophysical properties.
We have expertise in multiple MOAs and can optimize your existing payloads to improve both therapeutic window and ADC biophysical properties. We are a highly experienced team that can develop all types of assay (biophysical, in vitro and in vivo assessment of both PD and PK attributes), tailored to ADC projects.
Conjugating to an ADC enhances tumor delivery versus systemic exposure, increasing local drug concentration. With variable DARs, we can help control exposure and optimize PK.
We can use our experience in the area to examine how small changes in linker and payload chemistry, DAR and other factors can have dramatic impacts on both PK and efficacy.
We design ADCs to deliver compounds directly to the site of action, reducing off-target toxicity. Our medicinal chemistry expertise ensures stability while maintaining potency, so any compound that enters the systemic circulation after lysosomal clearance and cell death is rapidly eliminated.
We are small molecule focused, but also and have a strong track record in other modalities, including biologics, ADCs and peptides. We have a large protein science department with extensive experience in antibody and biologics expression, purification, QC and developability assessments.
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
